{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T08:18:40Z","timestamp":1763799520228,"version":"3.45.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhongguancun Precision Medicine Foundation","award":["ZLXGBXKYM-040-01"],"award-info":[{"award-number":["ZLXGBXKYM-040-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04845-x","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T08:17:24Z","timestamp":1763799444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0646-4871","authenticated-orcid":false,"given":"Yu","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-8017","authenticated-orcid":false,"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-3045","authenticated-orcid":false,"given":"Xiaoyan","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4044-1343","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"4845_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4845_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP (2023) The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 20:624\u2013639. https:\/\/doi.org\/10.1038\/s41571-023-00798-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4845_CR3","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"Y-L Zhang","year":"2016","unstructured":"Zhang Y-L, Yuan J-Q, Wang K-F et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985\u201378993. https:\/\/doi.org\/10.18632\/oncotarget.12587","journal-title":"Oncotarget"},{"key":"4845_CR4","doi-asserted-by":"publisher","first-page":"102080","DOI":"10.1016\/j.canep.2021.102080","volume":"76","author":"TJA Taylor","year":"2022","unstructured":"Taylor TJA, Wang H, Christian E (2022) Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol 76:102080. https:\/\/doi.org\/10.1016\/j.canep.2021.102080","journal-title":"Cancer Epidemiol"},{"key":"4845_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"4845_CR6","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"key":"4845_CR7","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327\u20133334. https:\/\/doi.org\/10.1200\/JCO.2012.44.2806","journal-title":"J Clin Oncol"},{"issue":"7","key":"4845_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","volume":"19","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, Parikh K, Banna GL et al (2024) Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review. J Thorac Oncol 19(7):973\u2013983. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.016","journal-title":"J Thorac Oncol"},{"key":"4845_CR9","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702\u20134711. https:\/\/doi.org\/10.1038\/onc.2008.109","journal-title":"Oncogene"},{"key":"4845_CR10","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","volume":"28","author":"TA Yap","year":"2010","unstructured":"Yap TA, Vidal L, Adam J et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. JCO 28:3965\u20133972. https:\/\/doi.org\/10.1200\/JCO.2009.26.7278","journal-title":"JCO"},{"key":"4845_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-011-1803-9","volume":"69","author":"P Stopfer","year":"2012","unstructured":"Stopfer P, Marzin K, Narjes H et al (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051\u20131061. https:\/\/doi.org\/10.1007\/s00280-011-1803-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4845_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6604108","volume":"98","author":"FALM Eskens","year":"2008","unstructured":"Eskens FALM, Mom CH, Planting AST et al (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80\u201385. https:\/\/doi.org\/10.1038\/sj.bjc.6604108","journal-title":"Br J Cancer"},{"key":"4845_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-011-1738-1","volume":"69","author":"H Murakami","year":"2012","unstructured":"Murakami H, Tamura T, Takahashi T et al (2012) Phase I study of continuous Afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy\/erlotinib\/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 69:891\u2013899. https:\/\/doi.org\/10.1007\/s00280-011-1738-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4845_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10637-012-9890-y","volume":"31","author":"J Marshall","year":"2013","unstructured":"Marshall J, Hwang J, Eskens FALM et al (2013) A phase I, open-label, dose escalation study of afatinib, in a 3-week-on\/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs 31:399\u2013408. https:\/\/doi.org\/10.1007\/s10637-012-9890-y","journal-title":"Invest New Drugs"},{"key":"4845_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00280-015-2826-4","volume":"76","author":"H Mukai","year":"2015","unstructured":"Mukai H, Masuda N, Ishiguro H et al (2015) Phase I trial of Afatinib plus Vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol 76:739\u2013750. https:\/\/doi.org\/10.1007\/s00280-015-2826-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4845_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","volume":"52","author":"S Wind","year":"2013","unstructured":"Wind S, Schmid M, Erhardt J et al (2013) Pharmacokinetics of Afatinib, a selective irreversible erbb family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 52:1101\u20131109. https:\/\/doi.org\/10.1007\/s40262-013-0091-4","journal-title":"Clin Pharmacokinet"},{"key":"4845_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-016-3201-9","volume":"79","author":"H Imai","year":"2017","unstructured":"Imai H, Kaira K, Naruse I et al (2017) Successful Afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemother Pharmacol 79:209\u2013213. https:\/\/doi.org\/10.1007\/s00280-016-3201-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4845_CR18","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.12998\/wjcc.v10.i19.6360","volume":"10","author":"C-C Lan","year":"2022","unstructured":"Lan C-C, Hsieh P-C, Huang C-Y et al (2022) Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. WJCC 10:6360\u20136369. https:\/\/doi.org\/10.12998\/wjcc.v10.i19.6360","journal-title":"WJCC"},{"key":"4845_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2007.06.001","volume":"58","author":"N Shinagawa","year":"2007","unstructured":"Shinagawa N, Yamazaki K, Asahina H et al (2007) Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 58:422\u2013424. https:\/\/doi.org\/10.1016\/j.lungcan.2007.06.001","journal-title":"Lung Cancer"},{"key":"4845_CR20","first-page":"319","volume":"34","author":"A Del Conte","year":"2014","unstructured":"Del Conte A, Minatel E, Schinella D et al (2014) Complete metabolic remission with gefitinib in a Hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res 34:319\u2013322","journal-title":"Anticancer Res"},{"key":"4845_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/1759-7714.12263","volume":"7","author":"J Luo","year":"2016","unstructured":"Luo J, Ni L, Wang M et al (2016) Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis. Thorac Cancer 7:251\u2013253. https:\/\/doi.org\/10.1111\/1759-7714.12263","journal-title":"Thorac Cancer"},{"key":"4845_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/JTO.0b013e3181d32287","volume":"5","author":"Y Togashi","year":"2010","unstructured":"Togashi Y, Masago K, Fukudo M et al (2010) Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 5:601\u2013605. https:\/\/doi.org\/10.1097\/JTO.0b013e3181d32287","journal-title":"J Thorac Oncol"},{"key":"4845_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/1744-9987.12531","volume":"21","author":"Y Iwafuchi","year":"2017","unstructured":"Iwafuchi Y, Saito I, Narita I (2017) Efficacy and safety of osimertinib in a Hemodialysis patient with advanced Non-Small cell lung cancer. Ther Apher Dial 21:416\u2013417. https:\/\/doi.org\/10.1111\/1744-9987.12531","journal-title":"Ther Apher Dial"},{"key":"4845_CR24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s10637-019-00851-y","volume":"38","author":"A Matsunashi","year":"2020","unstructured":"Matsunashi A, Fujimoto D, Hosoya K et al (2020) Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Invest New Drugs 38:1192\u20131195. https:\/\/doi.org\/10.1007\/s10637-019-00851-y","journal-title":"Invest New Drugs"},{"key":"4845_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.lungcan.2017.07.007","volume":"112","author":"T Tamura","year":"2017","unstructured":"Tamura T, Takagi Y, Okubo H et al (2017) Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis. Lung Cancer 112:225\u2013226. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.007","journal-title":"Lung Cancer"},{"key":"4845_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1159\/000531840","volume":"16","author":"K Tabata","year":"2023","unstructured":"Tabata K, Aoki M, Miyata R et al (2023) Successful treatment with osimertinib based on therapeutic drug monitoring in a Hemodialysis patient with Non-Small cell lung cancer: A case report. Case Rep Oncol 16:705\u2013710. https:\/\/doi.org\/10.1159\/000531840","journal-title":"Case Rep Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04845-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T08:17:25Z","timestamp":1763799445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04845-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4845"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04845-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}],"article-number":"112"}}